Recent Updates
Recently added Catalysts

TERN-101

Phase 2

NASH - Nonalcoholic Steatohepatitis | Small molecule | Infectious Disease |Terns Pharmaceuticals, Inc.|Last Updated: Aug 8, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment101
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04328077LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)PHASE2 COMPLETED 101 — — Jun 1, 2020May 1, 2021Aug 8, 2022 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
TERN-101DRUGInvestigational drug
PlaceboOTHERMatching placebo
Unlock Study Design Details